States May Bar Manufacturer Interference with 340B Contract-Pharmacy Delivery Without Federal Preemption; Trade-Group Intervention Requires a Distinct Defense

1. Introduction

This consolidated appeal sits at the intersection of the federal Section 340B Drug Pricing Program and states’ traditional authority to regulate pharmacies, drug distribution, and consumer protection. The plaintiffs—drug manufacturers and a trade association—challenged Louisiana’s Act 358, a statute that prohibits manufacturers and distributors from “deny[ing], restrict[ing], prohibit[ing], or otherwise interfer[ing]” with the acquisition or delivery of 340B drugs to contract pharmacies working for covered entities.

The disputes arise from a long-running controversy: while Congress created 340B to “stretch scarce healthcare dollars” for safety-net providers, HRSA guidance (1996; expanded in 2010) permitted covered entities to rely on contract pharmacies, and utilization “skyrocketed.” Some manufacturers responded with policies limiting contract-pharmacy distribution. After federal appellate decisions concluded that § 340B does not itself require delivery to unlimited contract pharmacies, states—including Louisiana—enacted statutes designed to prevent manufacturer “interference” with contract-pharmacy delivery.

The core issues before the Fifth Circuit were:

• Jurisdiction: whether the federal courts had subject-matter jurisdiction over an affirmative preemption challenge.
• Preemption: whether Act 358 is preempted by § 340B under field, conflict, or obstacle preemption.
• Constitutional claims: whether Act 358 violates the Takings Clause, the Contracts Clause, or due process (vagueness).
• Intervention: whether the Louisiana Primary Care Association (LPCA) properly intervened as a defendant under Rule 24.

2. Summary of the Opinion

3. Analysis

3.1 Precedents Cited

A. Federal jurisdiction for affirmative preemption suits

• Planned Parenthood of Hou. & Se. Tex. v. Sanchez and Shaw v. Delta Air Lines, Inc.: The court relied on the “well-established” principle that a plaintiff seeking injunctive relief against state officials on the ground of federal preemption presents a federal question under 28 U.S.C. § 1331. This framed the suits as classic Ex parte Young-style actions.
• Ex parte Young and Reed v. Goertz: These cases supplied the doctrinal vehicle: prospective declaratory/injunctive relief against state officers enforcing an allegedly unlawful state statute.
• Elam v. Kansas City Southern Railway Co.: Louisiana invoked Elam for the proposition that “defensive preemption does not create federal jurisdiction.” The Fifth Circuit distinguished it as a defensive-preemption/well-pleaded-complaint case between private parties, not an affirmative suit against state officials.
• New Orleans & Gulf Coast Ry. Co. v. Barrios: Reinforced the distinction between preemption asserted offensively against state action and preemption raised defensively in private litigation.

B. Controlling Fifth Circuit preemption precedent on 340B contract-pharmacy laws

• AbbVie, Inc. v. Fitch: This decision was the opinion’s centerpiece. The panel treated Fitch as controlling, emphasizing that Mississippi’s materially indistinguishable statute was not field-, conflict-, or obstacle-preempted by § 340B because § 340B is “silent” on “the distribution of drugs to patients” and “the role of pharmacies in this distribution.” The court rejected attempts to confine Fitch to the preliminary-injunction posture, stating it was “bound” by the on-point decision.
• English v. Gen. Elec. Co., Rice v. Santa Fe Elevator Corp., De Canas v. Bica: These supplied the general preemption framework and the “clear and manifest purpose” requirement, especially salient in “areas of law traditionally reserved to the states.”
• Franks Inv. Co. LLC v. Union Pac. R.R. Co. and City of El Cenizo v. Texas: Supported the presumption against preemption and the demanding showing required for field preemption.
• Oneok, Inc. v. Learjet, Inc. and Crosby v. Nat'l Foreign Trade Council: Provided high-level preemption principles: preemption may be express or implied, but must be rooted in congressional intent.

C. Sister-circuit and related 340B decisions anchoring the “silence” point

• Sanofi Aventis U.S. LLC v. U.S. Dep't of Health & Hum. Servs. and Novartis Pharms. Corp. v. Johnson: Cited for the proposition that § 340B does not itself require manufacturers to deliver discounted drugs to an unlimited number of contract pharmacies, underscoring the statute’s “silence about delivery conditions.”
• Pharm. Rsch. & Mfrs. of Am. v. McClain: Reinforced that Congress left pharmacy/delivery logistics unaddressed and that state laws barring interference with contract-pharmacy delivery do not “set or enforce discount pricing.” The opinion also noted McClain’s cert. denied status as part of the broader doctrinal landscape.
• Astra USA, Inc. v. Santa Clara Cnty.: Used for foundational description of 340B’s “straightforward bargain” and Congress’s design to ensure discounts for “local facilities that provide medical care for the poor,” while also emphasizing HHS’s role overseeing compliance.

D. Takings Clause

• Cedar Point Nursery v. Hassid: Supplied the categorical rule for physical takings (government physically acquires or occupies property) and the distinction between physical and regulatory takings.
• Pa. Coal Co. v. Mahon and Penn Cent. Transp. Co. v. City of New York: Provided the “goes too far” concept and the three-factor balancing test for regulatory takings (economic impact, investment-backed expectations, character of the government action).
• AbbVie, Inc. v. Fitch: Treated as dispositive on both physical-taking and regulatory-taking theories for materially identical state statutes.

E. Contracts Clause

• Sveen v. Melin: Provided the “two-step test” and the “substantial impairment” threshold inquiry; the panel ended at step one.
• Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co.: Key to the court’s “reasonable expectations” analysis, emphasizing that parties contract against a background of regulation—particularly in heavily regulated industries—so later supplementary regulation is less likely to be a substantial impairment.
• Allied Structural Steel Co. v. Spannaus: Distinguished as a case involving sudden, substantial retroactive obligations that effectively rewrote private obligations; Act 358 did not alter AstraZeneca’s Pharmaceutical Pricing Agreement (PPA) terms.
• NextEra Energy Cap. Holdings, Inc. v. Lake and United Healthcare Ins. Co. v. Davis: Used for modern Fifth Circuit framing of expectations and regulation in Contracts Clause analysis.

F. Vagueness

• United States v. Davis, United States v. Lanier, Connally v. Gen. Constr. Co.: Provided the core void-for-vagueness principles (fair notice; prevention of arbitrary enforcement).
• Coates v. City of Cincinnati: Anchored the distinction between laws that provide no standard at all versus those that require compliance with “imprecise but comprehensible” standards.
• Tex. v. Democratic Party v. Abbott and Groome Res. Ltd. v. Par. of Jefferson: Emphasized the especially high bar for vagueness challenges to civil statutes.
• Easom v. US Well Servs., Inc., United States v. Williams, and the interpretive principle of noscitur a sociis (also citing Yates v. United States): The court used the surrounding terms (“deny, restrict, prohibit”) to cabin “interfere,” rejecting the notion that it sweeps in routine auditing communications.
• Echo Powerline, L.L.C. v. Occupational Safety & Health Rev. Comm'n: Confirmed due process does not demand “utmost precision,” only “fair and reasonable warning.”

G. Intervention (Rule 24)

• Sierra Club v. Espy, Brumfield v. Dodd, Wal-Mart Stores, Inc. v. Texas Alcoholic Beverage Comm'n: Supplied the Fifth Circuit’s intervention standards and its general policy of liberal construction—while still placing the burden on the movant.
• Texas v. United States: Stated the four-part test for intervention as of right and highlighted that inadequate representation can be shown by a “may be” standard.
• Hopwood v. Texas: Functioned as the decisive comparator: when a State is defending its law, proposed intervenors must show their interests are actually different and inadequately represented, typically by identifying a distinct defense or litigation position the State will not advance. LPCA’s “more focused” or “business interests” rationale was treated as insufficient.

3.2 Legal Reasoning

A. Jurisdiction: preemption as a “sword” against state enforcement

The court framed the manufacturers’ suits as affirmative challenges to state enforcement—squarely within the Ex parte Young tradition—so the well-pleaded complaint rule problem that exists for defensive preemption (as in Elam v. Kansas City Southern Railway Co.) did not apply. Because the complaints sought prospective relief against a state official for enforcing a statute alleged to be preempted, federal-question jurisdiction existed.

B. Preemption: § 340B regulates pricing to covered entities, not delivery logistics

The panel’s preemption analysis is best understood as a “silence-plus-police-power” holding:

• Field preemption rejected: § 340B is detailed about ceiling prices, covered-entity eligibility, and anti-diversion/duplicate discount restrictions, but it does not occupy the field of drug distribution to patients or the role of pharmacies. That gap leaves room for state supplementation.
• Conflict/obstacle preemption rejected:
  • Act 358 does not expand who receives the 340B discount; covered entities still purchase at 340B prices and retain title, while contract pharmacies dispense as intermediaries.
  • Louisiana’s enforcement (via its Unfair Trade Practices and Consumer Protection Law) does not “clash” with HHS’s exclusive enforcement of § 340B because the two address different subject matter: HHS enforces the covered entity’s ability to purchase at/below the ceiling price; Act 358 enforces non-interference with acquisition/delivery to contract pharmacies.
  • The court rejected the characterization that Act 358 is a “pricing” law; it is a conduct regulation that attaches after a covered entity’s purchase and delivery instruction.

The presumption against preemption did substantial work: because public health and consumer protection are core state police powers, the panel required a “clear and manifest” congressional intent to displace state regulation—absent here.

C. Takings: non-interference is not compelled physical transfer, and Penn Central does not favor manufacturers

AbbVie’s physical-taking theory failed because Act 358 does not compel manufacturers to transfer drugs to third parties without compensation or to sell more than § 340B requires. The statute prohibits interference with covered entities’ post-purchase distribution choices; manufacturers still receive the discounted amounts to which they are entitled under § 340B.

Under Penn Cent. Transp. Co. v. City of New York, the court—tracking AbbVie, Inc. v. Fitch—found: (1) the economic impact was limited because manufacturers still receive “a large percentage of the market price” for most drugs; (2) investment-backed expectations were not significantly disrupted because contract pharmacies have been a foreseeable feature of the 340B landscape for decades; and (3) the character of the government action strongly favored the State given the public-health access rationale.

D. Contracts Clause: no substantial impairment of the federal PPA

AstraZeneca’s Contracts Clause claim depended on treating Act 358 as effectively modifying its PPA with HHS. The court rejected that framing because Act 358 does not alter PPA terms and regulates relationships to which the manufacturer is not a party (covered entities and their contract pharmacies). Critically, the PPAs are silent on delivery logistics; what is absent from the bargain cannot be “substantially impaired” by state law in the way the Contracts Clause contemplates.

The court further held that reasonable expectations in a heavily regulated industry are shaped by the possibility of additional state regulation, relying on Energy Rsrvs. Grp., Inc. v. Kan. Power & Light Co. and distinguishing Allied Structural Steel Co. v. Spannaus as an outlier involving retroactive rewriting of obligations.

E. Vagueness: “interfere” is cabined by context and due process tolerates reasonable breadth in civil statutes

PhRMA targeted “interfere” as indeterminate. The court used noscitur a sociis to interpret “interfere” in light of “deny, restrict, prohibit,” concluding the statute reaches obstructive conduct, not routine audit communications. Given the elevated vagueness threshold in civil statutes, Act 358 provided adequate notice and an enforceable standard.

F. Intervention: a State defendant triggers a strong presumption of adequate representation

Applying Hopwood v. Texas, the court held LPCA failed Rule 24(a)(2)’s inadequate-representation requirement. When a State defends a statute, the intervenor must show interests are actually different and “may be” inadequately represented—typically by identifying a distinct defense or a divergence that affects litigation strategy. LPCA offered only a generalized claim of different emphasis (public interest versus member business interests) without explaining any distinct defense or how Louisiana’s representation would be diluted.

3.3 Impact

• State regulatory space affirmed: The decision fortifies state authority to regulate drug delivery and pharmacy contracting surrounding 340B, so long as the state law does not attempt to alter federally set pricing mechanics or covered-entity eligibility.
• Manufacturer policy constraints increase: Within the Fifth Circuit, manufacturers face substantial litigation headwinds when attempting to restrict covered entities’ use of contract pharmacies via policies that could be characterized as “interference” with acquisition or delivery.
• Litigation posture clarified: The court’s jurisdiction discussion preserves the viability of affirmative preemption suits against state officials, distinguishing defensive-preemption jurisdiction limitations.
• Intervention doctrine tightened in state-defense cases: Trade associations and other aligned private entities cannot assume intervention as of right merely because they are affected; they must articulate a concrete divergence from the State’s defense.
• Pressure on Congress and HHS: The opinion underscores the practical consequence of federal “silence”: states will fill gaps, potentially producing a patchwork of delivery rules unless Congress amends § 340B or HHS receives clearer authority.

4. Complex Concepts Simplified

• 340B “covered entities”: Safety-net providers (clinics/hospitals and similar institutions) that may buy certain outpatient drugs at or below a federally defined “ceiling price.”
• Contract pharmacies: Independent pharmacies that dispense 340B drugs on behalf of covered entities when the entity lacks an in-house pharmacy or chooses to use external dispensing.
• Preemption (field vs. conflict vs. obstacle):
  • Field: Congress so fully regulated an area that states have no room to act.
  • Conflict: It’s impossible to comply with both state and federal law.
  • Obstacle: State law stands as an unacceptable obstacle to Congress’s objectives.
• Takings (physical vs. regulatory):
  • Physical: the government forces an occupation or acquisition of property.
  • Regulatory: the government limits how property can be used; courts apply the Penn Cent. balancing factors.
• Contracts Clause “substantial impairment”: A threshold showing that the law meaningfully rewrites the bargain or defeats reasonable expectations grounded in the contract’s terms and regulatory backdrop.
• Void-for-vagueness: A law is unconstitutional only if people of common intelligence must guess at what is prohibited and enforcement becomes arbitrary; civil statutes get more leeway.
• Intervention as of right (Rule 24(a)(2)): Even if an intervenor is affected, intervention can be denied if the existing party—here, the State—is presumed to represent the intervenor’s interests and no concrete inadequacy is shown.

5. Conclusion

AstraZeneca v. Murrill solidifies a Fifth Circuit rule with two principal takeaways. First, state “non-interference” statutes protecting covered entities’ use of contract pharmacies are not preempted by § 340B where federal law is silent on delivery logistics and the state law operates within traditional police powers. Second, when a State is already defending its statute, aligned private parties seeking to intervene must do more than echo the State’s position; they must show a genuine risk of inadequate representation through a distinct interest that changes the defense.